Gene

ABL1

ABL proto-oncogene 1, non-receptor tyrosine kinase

Explore in graph →CI-GENE-00000153HGNC:76 ENSG00000097007 NCBI 25 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (617)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 501–550 of 617 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ABL1 V289I + ABL1 Fusion1
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Does Not Support Resistance	3

Cohorts

Alteration frequency by cohort (122)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved122 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Cutaneous Squamous Cell Carcinoma (DFCI, Clin Cancer Res 2015) cscc_dfarber_2015	Skin Squamous Cell Carcinoma	Ssm

Literature

Linked publications (65)

25 per page, newest first.

pubmedPublishedShowing 26–50 of 65 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
· Blood · 2007 · PMID 17264298 · validated civic_curation pubmed
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
· Blood · 2003 · PMID 12623848 · validated civic_curation pubmed
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
· N Engl J Med · 2006 · PMID 16775234 · validated civic_curation pubmed
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
· Nature · 2015 · PMID 25686603

ABL1 V299L + ABL1 Fusion11
Axitinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID4537 In an in vitro study, pro-B Ba/F3 cell line expressing V299L mutation in the ABL1 portion of the BCR-ABL1 fusion protein (overexpression) demonstrated increased sensitivity to axitinib treatment (IC50… (full text at CIViC) PMID 26582647 · Zabriskie et al., 2016 · Open in CIViC	civic
〃	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID7767 In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed decreased incorporation when harboring fusions with t… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC	civic
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Supports Reduced Sensitivity	1	accepted	EID4538 This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC	civic
〃	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4539 In an in vitro study, a Ba/F3 murine cell line stably expressing the V299L mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to bosutinib treatment (I… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Supports Resistance	3	accepted	EID4541 In a study of 51 imatinib-resistant chronic myeloid leukemia patients, patients with the V299L mutation in the ABL1 portion of the BCR-ABL1 gene fusion (n=3) were associated with acquired resistant to… (full text at CIViC) PMID 27485109 · Soverini et al., 2016 · Open in CIViC	civic
〃	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Supports Resistance	1	accepted	EID4540 This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
〃	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	3	accepted	EID6216 In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasat… (full text at CIViC) PMID 15705718 · Burgess et al., 2005 · Open in CIViC	civic
〃	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	accepted	EID6247 In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC	civic
Imatinib Mesylate	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	B	Supports Resistance	1	accepted	EID6982 In a study of 39 chronic phase CML patients with BCR-ABL variants, V299L was seen in two imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nin… (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC	civic
Dasatinib + Imatinib MesylateCombination	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	accepted	EID6241 In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC	civic
Nilotinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID2862 In an in vitro study, a Ba/F3 cell line stably expressing the V299L mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 1.34-fold)… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic

ABL1 V299L + ABL1 Fusion11

Axitinib

Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS

Predictive

Supports Sensitivity Response

accepted

EID4537

In an in vitro study, pro-B Ba/F3 cell line expressing V299L mutation in the ABL1 portion of the BCR-ABL1 fusion protein (overexpression) demonstrated increased sensitivity to axitinib treatment (IC50… (full text at CIViC)

PMID 26582647 · Zabriskie et al., 2016 · Open in CIViC